

July 17, 1967

Dr. Leo Winter, Jr., President
Leo Winter Associates, Inc.
211 East 43rd Street
New York, New York 10017

Dear Dr. Winter:

I have read the data on fenazoxine (Riker - 738), with a great deal of interest. As is usual for such presentation, some of the essential human data which provides the basis for the recommendation that the drug be assessed as an anti-depressant is lacking.

I have read most closely the initial human data reports and am particularly interested in those of Pfeiffer, Okun and Baltes (002, 005).

We are interested in assessing compounds of this class.

Before undertaking a review of a protocol, I would ask that some of the additional data available to you be shared with my associates and myself. With regard to Carl Pfeiffer's data, I would be interested in the report itself and any EEG samples which he may have submitted.

With regard to Dr. Okun, has his method been applied to barbiturates and if so, is R-738 similar or different?

With regard to Dr. Baltes' study 002, he may have concluded that R-738 had some anticholinergic activity. Is this true? In his other studies (004 - 006) the data is unclear as to whether depression and stimulant activity occurred in the same subject or different and whether he interpreted the data as consistent with an antidepressant.

My present laboratories have two populations available - the more usual out-patients of largely a lower class origin, exhibiting the complex psychotic and neurotic diagnoses. In addition, there is a specialized population of substance abusers, mostly narcotic addicts who provide the basis for specialized studies of new compounds which may be useful in the treatment of substance abuse. I am

Dr. Winter

-2-

July 17, 1967

particularly interested in central nervous system stimulants and drugs which may have an antidepressant quality, since clinical depression is a common manifestation of narcotic addiction.

In addition to clinical studies, we have been interested in the use of the electroencephalogram as an index to new drug studies. It is for this reason that I am particularly interested in the data collected by Carl Pfeiffer.

Thank you very much for the opportunity to read the data of fenazoxine. If the additional information is available, I would be pleased to meet with you after we have had a chance to read it.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp